IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy.
IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy -
Panminerva Med. 2020 Sep;62(3):131-134. doi: 10.23736/S0031-0808.19.03795-9.
The aim of this registry study was to evaluate the effects of Robuvit® (extract from oak wood), in otherwise healthy subjects (aged 50 to 65 years) who complained of decreased general vigor. Robuvit® has been shown to be effective in convalescence, chronic fatigue syndrome and post-traumatic stress disorder.
The standard management (SM) for this condition included diet, regular daily routines and regular exercise. All subjects had increased oxidative stress (>350 Carr Units) at inclusion. Two groups, SM and SM+Robuvit® supplementation, were formed. Robuvit® was supplemented at a dose of 300 mg/day for 4 weeks. A visual analogue scale line or vigor visual analogue line score of the most common problems associated with a decrease in vigor was used by all included subjects.
Forty subjects were included in the study. 20 in the SM group and 20 in the SM + Robuvit® supplement group. All subjects completed the 4-week study; both groups improved with the health program and under SM. No drop-outs and no side effects were recorded; a very good tolerability for the supplement was reported. At 4 weeks, the scores in Robuvit®-supplemented subjects, were significantly higher for all vigor-related items in comparison with the scores of subjects managed with the SM only (P<0.05). In parallel, oxidative stress (plasma free radicals expressed in Carr units) was statistically lower (P<0.05) in Robuvit®-supplemented subjects than in SM only after 4 weeks.
The concept of vigor, partially associated with premature aging, decreased level of activity and exercise, a sedentary lifestyle, appears to be a quantifiable entity. Robuvit® supplementation - previously shown to be effective in chronic fatigue syndrome, convalescence, post-mononucleosis, PTSD or in liver failure - improves vigor; further evaluations need to be planned according to the concept of this pilot registry.
本注册研究的目的是评估 Robuvit®（橡木提取物）对主诉一般活力下降的健康受试者（年龄 50 至 65 岁）的影响。Robuvit®已被证明在康复、慢性疲劳综合征和创伤后应激障碍中有效。
该疾病的标准管理（SM）包括饮食、日常常规和定期运动。所有受试者在纳入时均有较高的氧化应激（>350 卡尔单位）。将患者分为 SM 组和 SM+Robuvit®补充组。Robuvit®以 300mg/天的剂量补充 4 周。所有纳入的患者均使用与活力下降相关的最常见问题的视觉模拟量表线或活力视觉模拟量表评分。
本研究共纳入 40 例患者，其中 SM 组 20 例，SM+Robuvit®补充组 20 例。所有患者均完成了 4 周的研究；两组均通过健康计划和 SM 得到改善。无脱落病例，无不良反应记录；报告补充剂具有很好的耐受性。4 周时，与仅接受 SM 管理的患者相比，补充 Robuvit®的患者在所有与活力相关的项目中的评分均显著更高（P<0.05）。同时，与仅接受 SM 管理的患者相比，补充 Robuvit®的患者在 4 周后，氧化应激（以卡尔单位表示的血浆自由基）显著降低（P<0.05）。
活力的概念，部分与早衰、活动和运动水平下降、久坐的生活方式有关，似乎是一种可量化的实体。Robuvit®补充剂-先前在慢性疲劳综合征、康复、单核细胞增多症后、创伤后应激障碍或肝衰竭中显示有效-可改善活力；需要根据本注册研究的概念进一步计划评估。
